← Back to Home

Making surviving retinal cells light-sensitive: Optogenetic therapy planned for a phase 2 geographic atrophy trial

After photoreceptors are lost, can the remaining neural circuits receive light again? Nanoscope plans to seek an answer through a randomized controlled trial. Current supporting evidence comes from a small Stargardt disease study and animal models; the therapy has not yet been shown to improve vision in patients with geographic atrophy.

By SURL BioNews

For patients with geographic atrophy, slowing lesion enlargement and regaining lost vision are two different hopes. This advanced form of age-related macular degeneration causes progressive loss of photoreceptors. Currently approved therapies in the United States can slow the progression of atrophy but have not been shown to restore vision. Nanoscope Therapeutics is advancing an optogenetic gene therapy that aims to enable surviving retinal cells to take over light sensing, and plans to test this concept in a phase 2 randomized controlled trial.

An October 9 report by *Ophthalmology Times* covering the American Academy of Ophthalmology (AAO) annual meeting summarized results for sonpiretigene isteparvovec, formerly known as MCO-010, in patients with Stargardt disease and in nonhuman primate models. The company’s October 6 announcement also listed related scientific posters presented by David S. Boyer and stated that the phase 2 geographic atrophy program was expected to begin in 2026. However, the available data provide a rationale for proceeding to a trial; they do not yet constitute evidence that the therapy is effective in patients with geographic atrophy.

The therapy uses a single intravitreal injection to deliver a gene encoding the light-sensitive protein opsin into retinal bipolar cells through a viral vector. Bipolar cells normally relay visual signals. By adding the light-sensitive protein, researchers hope these cells can respond directly to light and use the remaining neural circuits to transmit signals. This pathway bypasses damaged photoreceptors, and its design does not require changing the therapeutic gene for individual disease-causing mutations.

Human evidence currently comes mainly from Stargardt disease, an inherited macular disorder. The conference report stated that patients whose atrophy was confined to the macula gained an average of approximately 12 letters on a visual acuity chart, but did not specify the size of this subgroup or the duration of follow-up. Separately, according to the published STARLIGHT study cited in the AAO coverage, 6 adults gained an average of 5.5 letters in best-corrected visual acuity at 48 weeks. These two figures cannot simply be treated as the same result. The studies were small, open-label, and lacked control groups, making it difficult to rule out factors such as measurement variability or to directly infer how older patients with macular degeneration would respond.

Animal studies provide another layer of evidence. In an interview at the EURETINA meeting, Jordi Monés said the team used lasers to selectively damage the outer retina of nonhuman primates to simulate photoreceptor loss. They observed opsin expression in more than 70% of target cells, along with stronger electrical responses on multifocal electroretinography. This suggests that the cells may acquire light sensitivity, but improved electrical signals do not mean that patients can see objects clearly. The laser model also cannot fully reproduce the long-term changes of human disease, and the related preclinical data have not yet been published in a peer-reviewed journal.

According to the design Monés previously described to *Modern Retina*, the geographic atrophy trial will initially focus on patients with advanced disease whose fovea is already involved and whose vision is severely impaired. Improvement in best-corrected visual acuity will be the primary outcome measure, with quality of life and daily functioning also tracked. The study must also formally answer a key question: could making bipolar cells directly sensitive to light interfere with vision that remains around the lesions? Preliminary observations in Stargardt disease have not shown this, but the answer for patients with geographic atrophy still awaits confirmation in a trial.

The research team plans to proceed directly to phase 2 without conducting a separate phase 1 trial in the geographic atrophy population. As of the publication of the October 9 report, the outlet had not found a registration record for this trial, so its start date and full design remain to be disclosed. The randomized controlled study will need to clarify more than whether patients gain letters on a visual acuity chart. It must also determine whether any improvement lasts, whether it translates into visual abilities in daily life, and whether the treatment preserves patients’ existing visual function.

References

  1. Ophthalmology Times
  2. Nanoscope Therapeutics
  3. Modern Retina
  4. Ophthalmology Times